Janssen gets pri­or­i­ty re­view for prostate can­cer com­bo; Im­muno­Gen re­ports Q1 Ela­here sales

Janssen’s com­bi­na­tion ther­a­py of ni­ra­parib with abi­raterone ac­etate plus pred­nisone for the treat­ment of BCRA-pos­i­tive metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer (mCR­PC) is mov­ing along.

Jannsen post­ed on Twit­ter on Fri­day morn­ing that its sub­mis­sion to the FDA for the com­bi­na­tion ther­a­py has re­ceived a pri­or­i­ty re­view. The drug com­bo was sub­mit­ted for an NDA back in March.

UP­DATE: Our sub­mis­sion to the U.S. FDA for a new tar­get­ed ther­a­py for pa­tients with BR­CA-pos­i­tive metasta­t­ic cas­tra­tion-re­sis­tant #Prostate­Can­cer #mCR­PC has re­ceived Pri­or­i­ty Re­view. https://t.co/56gMkdG­WQI https://t.co/UUmAs7Ch­dI

— Janssen Glob­al (@Jans­sen­Glob­al) April 28, 2023

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER